The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC

Hematology MORE >>

A biologics license application for SL-401 (tagraxofusp, Elzonris) has been granted a priority review by the FDA as a treatment for patients with blastic plasmacytoid dendritic cell neoplasm,  Stemline Therapeutics, the developer of the novel stemness inhibitor, has announced.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.